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Background: Inflammatory bowel diseases, ulcerative colitis and Crohn’s disease are considered to be of
autoimmune origin, but the etiology of irritable bowel syndrome remains elusive. Furthermore, classifying patients
into irritable bowel syndrome and inflammatory bowel diseases can be difficult without invasive testing and holds
important treatment implications. Our aim was to assess the ability of gene expression profiling in blood to
differentiate among these subject groups.
Methods: Transcript levels of a total of 45 genes in blood were determined by quantitative real-time polymerase
chain reaction (RT-PCR). We applied three separate analytic approaches; one utilized a scoring system derived from
combinations of ratios of expression levels of two genes and two different support vector machines.
Results: All methods discriminated different subject cohorts, irritable bowel syndrome from control, inflammatory
bowel disease from control, irritable bowel syndrome from inflammatory bowel disease, and ulcerative colitis from
Crohn’s disease, with high degrees of sensitivity and specificity.
Conclusions: These results suggest these approaches may provide clinically useful prediction of the presence of
these gastro-intestinal diseases and syndromes.Background
Inflammatory bowel diseases (IBD), Crohn’s disease
(CD), Celiac’s disease (CeD) and ulcerative colitis (UC)
are chronic relapsing remitting inflammatory conditions
affecting the gastrointestinal tract, primarily the small
intestine and colon [1]. CD is most frequently diagnosed
in patients in their 20s and UC in their 30s; however, the
diagnosis can be made at any age [2]. IBD diagnosis is
often straightforward, as disease can be seen by endos-
copy or imaging modalities. However, diagnosis can be
difficult as patients may experience symptoms consistent
with IBD but ultimately have other diagnoses including
functional gastrointestinal disorders such as irritable
bowel syndrome (IBS) [3-6]. Patients with IBS can have
symptoms very similar to those with IBD. IBD can be
limited to difficult to evaluate areas of the GI tract such
as isolated small bowel disease. Also, within IBD, differ-
entiating between CD and UC can be difficult, especially* Correspondence: philip.s.crooke@vanderbilt.edu
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reproduction in any medium, provided the orwithin patients with severe inflammatory activity, often
termed indeterminate colitis [7]. When the clinical pres-
entation is severe and an operation including colectomy
is indicated, differentiating CD and UC is imperative, as
ileal pouch-anal anastomosis (IPAA) is generally contra-
indicated in CD due to high morbidity [8].
Developing biomarkers that can be easily obtained and
allow for the correct diagnosis early into evaluation can
avoid costly interventions that expose patients to mul-
tiple unnecessary procedures. Blood markers for both
IBD and IBS have been sought for decades. For IBD,
perinuclear antineutrophil cytoplasmic antibody (p-ANCA)
and anti-Saccharomyces cerevisiae antibody (ASCA) have
been reported to be markers for UC and CD, respectively.
However, p-ANCA is also detected in 10–40% of patients
with CD and ASCA is detected in 6–14% of patients with
UC [1]. Other markers increased in subjects with CD
include antibodies to (a) Escherichia coli outer mem-
brane porin C (Omp-C), (b) protein from Pseudomonas
fluorescens [9] and (c) flagellin c-BIR1 (anti-CBIR1)
[10], but these markers remain insensitive. In patients
with indeterminate colitis, those with one or moreLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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body to Pseudomonas fluorescens), and Omp-C, have
significantly higher post-operative complications [11].
Other inflammatory biomarkers such as C-reactive pro-
tein, fecal calprotectin, and fecal lactoferrin differentiate
IBD from other gastrointestinal disorders such as IBS
[5], but tests do not differentiate among various types
of inflammatory colitides [12].
Additional biomarker candidates include DNA variants,
differences in RNA transcript abundances, including
mRNAs, microRNAs, long intergenic non-coding RNAs,
proteins, or metabolites. A general view is that different
profiles of biomarkers could provide useful information
to guide clinical decision-making; from diagnosis to
choice of optimal therapies and in some cases these
biomarker profiles are being implemented in clinical
practice [3,12-24]. Searches for optimal biomarker profiles
can be achieved using clustering methods e.g., heirarchical
clustering, K-means clustering, which depend upon the
general ability to find common features across a sample
population or forms of linear discriminate analysis, which
depend upon the ability to find linear combinations of fea-
tures that have the ability to separate two or more classes.
The former method is a common method to analyze large
numbers of features, such as microarray data whereas the
latter is a more common method for analysis of smaller
numbers of features. Both methods are suitable for further
analyses using machine learning methods such as support
vector machines, logistic regression, principal components
analysis or prediction analysis for microarrays. Using a
form of linear discriminant analysis, we have attempted to
employ mRNA transcript profiles to distinguish between
subjects with multiple sclerosis and other comparator
groups [25,26]. Our results clearly demonstrate that
mRNA transcript profiling has the capacity to distinguish
between MS, even early in the disease process, and homo-
geneous comparator groups, such as healthy subjects
(CTRL), or subjects with clinically related diseases such as
neuromyelitis optica or transverse myelitis. Thus, these
binary comparisons can produce a test of exclusion of
multiple sclerosis. Here, we applied this approach to IBD
and IBS. Our results demonstrate that distinct mRNA pro-
files accurately discriminate IBD from CTRL, IBS from
CTRL, IBD from IBS, and CD from UC with high degrees
of sensitivity and specificity. We propose these approaches
may provide useful guides for clinical decision-making.
Methods
Human subjects
Blood samples collected in PAXgene tubes were obtained
from CTRL, IBS, CeD, CD or UC subjects. Diagnosis of
IBD, both CD and UC, was made by colonoscopy or sig-
moidoscopy and tissue biopsy to localize inflammation to
all layers of the intestinal wall (CD) or only the inner lininglayer (UC). Diagnosis of IBS was made by the absence of
pathologic damage in the colon after examination by colon-
oscopy or sigmoidoscopy. Inclusion criteria were diagnosis
by a gastro-intestinal specialist using these methods. Age,
race and gender were not statistically different among the
different study groups. Time of blood draw, for example,
morning/afternoon clinics, was also not statistically signifi-
cant among the different study groups. Relevant institu-
tional review board (Vanderbilt University School of
Medicine and University of Texas Southwestern Medical
School) approval was obtained from all participating sites.
Informed consent was obtained from all subjects.
MRNA transcript determination
Total RNA was purified using Qiagen’s RNA isolation
kits using standard protocols and was reverse-
transcribed using poly-A primers uisng Superscript III
(Invitrogen, Carlsbad, CA, USA). A TaqMan Low Dens-
ity Array (TLDA) was designed to analyze expression
levels of 44 target genes and of four housekeeping genes
in 300 ng cDNA. The gene probes on the TLDA plate
were: ABR, ACTB, ACTR1A, ADAMTSL4, ANAPC1,
APOBEC3F, ASL, B2M, BRCA1, CD55, CDH1, CDKN1B,
CHEK2, CSF3R, CTSS, EPHX2, EXT2, FOS, FOSL1,
GAPDH, GATA3, GNB5-1, GNB5-1, GSTM4, HLA-DRA,
HRAS, IFI27, IL11RA, JUN, KRAS, LEPREL4, LLGL2,
NRAS, OAS1, ORC1L, PGK1, PMAIP1, POU6F1, RAN
GAP1, SC65, SPIB, TAF11, TBP, TGFBR2, TP53-1 TP53-2,
TXK. GNB5-1 and −2 and TP53-1 and −2 interrogate
different exon-intron junctions [26]. Inclusion of the
specific gene targets was based upon the following criteria:
(a) previous studies demonstrating differential expression
among control and multiple autoimmune diseases, (b) pro-
tein products possess known inflammatory functions, (c)
expression levels change in response to pro-inflammatory
stimuli (cytokines), and/or (d) protein products have
known roles in cell cycle progression and/or apoptosis.
Patient diagnosis was blinded for all experimental pro-
cedures. Relative expression levels were determined
directly from the observed threshold cycle (CT).
Ratioscore and support vector machine (SVM) methods
Principal Component Analysis (PCA) was applied dir-
ectly to the normalized gene expression data using
MATLAB’s Bioinformatics Toolkit (The MathWorks,
Inc.) and other techniques to identify a lower dimen-
sional space of gene expressions that could be used to
classify controls from cases. The results were disappoint-
ing and we concluded that looking at ratios of the gene
expression data may be a more productive approach.
The computational algorithm and permutation testing
strategy employed to identify discriminatory combina-
tions of ratios to create the ratioscore (our terminology)
have been previously described [26]. For completeness,
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Method below. Let D denote the set of gene-expression
levels associated with the disease group and C denote
the set of gene-expression levels associated with the con-
trol group. The algorithm searches for the “best” set of
gene ratios that partitions D and C:
 80% of the control and disease groups are randomly
selected. Gene-expression level ratios are formed for
elements in D and C. For each ratio, the number of
elements in the disease group that are larger than
the largest ratio in the control group is computed.
The top 500 ratios that separate elements in D and
C are saved. This calculation is repeated 200 times
resulting in a set of 200 subsets of ratios (each
subset having 500 ratios).
 The 500 subsets are then processed looking for the
smallest number of ratios, R={r1, r2, . . ., rn}, that
produce the maximum of separation of D and C.
Associate with each of the ratios in R, there are
threshold values,T={t1, t2, . . ., tn}, which correspond
to the highest value in the control group for each
of the ratios in R.
 For each member of the disease group D, the ratios
in R are computed, {α1, α2, . . ., αn}. If αi ≥ ti, then
we assign the ratio a 1; otherwise, it is assigned a 0.
In this way, we generate an n-tuple of 1’s and 0’s for
each member of D. For example, if n = 6, then a
typical 6-tuple would be {1,1,0,0,1,0}. This would
mean that this individual in the disease group would
have 3 ratios that exceed the corresponding ratios in
the control group.
 Lastly, the percentage of members in the disease group
that have nonzero n-tuples is calculated. The larger the
percentage, the better the separation of D and C.
The algorithm alllows one to identify the smallest number
of ratios that partitions the case and control groups.
Two support vector machines (SVM) were independ-
ently created and trained using ratios identified by the
Ratioscore Method. The first SVM was coded in Mathe-
matica (Wolfram Research, Inc.) and the second SVM
employed LS-SVMLab software (http://www.esat.kuleuven.
be/sista/lssvmab). We decided to use the two independ-
ently developed SVM since the choice of kernels,
optimization algorithms, and the training algorithms can
produce differing results. There was little difference in the
performance of the two machines when classifying the dif-
ferent case–control combinations. To confirm the results
of the Ratioscore Method and the SVM approaches, logis-
tic regression was employed to separate to the case and
control sets using the gene ratios. Its performance was in
line with the other two approaches and hence, we have
chosen not to report these results.Statistical analysis
The Welch’s-corrected T-test not assuming equal var-
iances was employed to calculate p-values in two-way
comparisons. Fisher’s exact test was employed to calculate
p-values in 2 by 2 comparisons. The Bonferroni’s method
was employed to correct for multiple testing [27].
Results
Gene-expression patterns in distinct gastrointestinal
diseases
CTRL, IBD (CD and UC), IBS subjects were recruited
from multiple sites within the United States. Demo-
graphic characteristics of the different gastrointestinal
disease cohorts were not statistically different from the
CTRL cohort (Table 1). We measured expression patterns
of a common set of genes assayed using a common plat-
form in CTRL and subjects with different gastrointestinal
conditions, CD and UC, IBS, and CeD. Genes for analysis
were selected from prior microarray studies [20,26]. Gene
transcript levels were determined by quantitative RT-PCR
and normalized to GAPDH transcript levels. We employed
a heatmap to depict those genes differentially expressed in
individual subject cohorts relative to the CTRL cohort,
p-value < 0.05 (after Bonferroni correction for multiple
testing; see Figure 1 with red = over-expressed gene,
green = under-expressed gene). Ratios of transcript
levels of individual genes in the indicated disease cohorts
relative to GAPDH were calculated and depicted within
each box. Each disease exhibited an underlying unique
pattern of gene-expression. However, these profiles were
sufficiently overlapping to prohibit accurate discrimination
of one disease from another disease using the expression
profile alone. For example, while PGK1 was over-expressed
in all four conditions, ABR, ACTR1A, EXT2, HRAS, and
KRAS were over-expressed in CeD and IBS but not CD
and UC. Similarly, APOBEC3F, ASL, and SPIB were under-
expressed in CD and UC, but not CeD and IBS. Other
genes, ANAPC1, RANGAP1, and TP53, were only under-
expressed in CD. Certain genes, e.g., APOBEC3F, ASL,
GNB5, SPIB, were only under-expressed relative to the
CTRL cohort, while other genes, e.g., ACTB, GATA3,
HRAS, and LLGL2, were under-expressed in specific dis-
ease cohorts relative to CTRL but over-expressed in other
disease cohorts relative to CTRL. Thus, each gene was
differentially expressed in at least one disease cohort
relative to CTRL. However, each individual disease cohort
did not possess a unique expression profile distinguishing
it from all other disease cohorts. For these reasons, we
decided to look at other separation techniques.
Discrimination of IBD or IBS from CTRL based upon
gene-expression ratios
Initially, we employed standard methods of microarray
analyses including unsupervised heirarchical clustering,
Table 1 Demographic characteristics of the different subject populations
# AGE yrs P* GENDER (% F) P ETHNICITY (% C/AA/As/H) P
IBD 97 40±9 NS 62 NS 92/5/0/1 NS
CD 46 38±10 NS 63 NS 91/4/0/0 NS
UC 40 41±8 NS 59 NS 93/5/0/2 NS
IBS 44 43±10 NS 79 NS 90/7/0/3 NS
CeD 16 44±12 NS 69 NS 100/0/0/0 NS
CTRL 113 41±11 67 89/9/0/2
*P calculated by Student T-test (Age) or Fisher’s exact test, NS: p-value > 0.05.
†C, Caucasian; AA, African American; As, Asian; H, Hispanic.
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nents analysis using the TIGR microarray software Mul-
tiexperiment Viewer to segregate patient groups. After
normalization to GAPDH, gene expression data from
IBD samples or IBS samples and CTRL samples were
analyzed using unsupervised and supervised heirarchical
clustering using all genes or only those genes whose ex-
pression was statistically significant using the supervised
T-test. We found that unsupervised heirarchical cluster-
ing segregated 72% of IBD samples in one major branch
and 28% of IBD samples in the second major branch.
Similarly, 36% of CTRL samples were segregated into
the branch with most of the IBD samples while 64% of
CTRL samples were segregated into the alternate
branch. Comparison of IBS and CTRL using unsuper-
vised heirarchical clustering also did not produce the
desired level of discrimination between case and control
cohorts. Supervised heirarchical clustering and principal
components analysis produced a similar low level of
overall accuracy.
For these reasons, we turned to a type of linear dis-
criminant analysis classifier (Ratioscore Method) that we
employed previously to discriminate subjects with mul-
tiple sclerosis from different control cohorts. We
employed a search algorithm to identify those ratios of
gene-expression levels in which the greatest number of
subjects in the test group possessed a ratio value greater
than the highest ratio value in the comparator group.
We employed a second algorithm to perform permuta-



















































CTRL 0.0009 4.06 0.43 0.0067 0.0040 0.0065 2.96 0.0006 0.106 0.0002 0.0079 1.00
0.0007 2.44 0.41 0.0039 0.0024 0.0039 4.96 0.0007 0.191 0.0002 0.0072 1.01
UC 0.0007 4.54 0.48 0.0069 0.0023 0.0042 5.50 0.0006 0.111 0.0001 0.0082 1.00
Celiac 0.0017 4.16 0.67 0.0065 0.0038 0.0062 3.21 0.0010 0.108 0.0002 0.0141 1.01
IBS 0.0016 6.66 0.69 0.0069 0.0036 0.0064 2.84 0.0006 0.111 0.0002 0.0115 1.02
Figure 1 Gene-expression profiles in multiple gastrointestinal disorde
quantitative RT-PCR and normalized to expression of GAPDH. Expression lev
not statistically different between CTRL and any disease cohort. Results are
levels of GAPDH using the formula: 2(GAPDH CT -target gene CT ). Genes are iden
Bonferroni’s correction) increased (red boxes) or decreased (green boxes) eoptimum set of discriminatory ratios. CeD was excluded
from this analysis due to the low number of cases in this
cohort. Examination of expression levels of ratios of
genes rather than individual genes offered the following
advantages. First, ratios normalized for differences in
mRNA or cDNA template quantity and quality among
different samples. Second, ratios obviated the need for
inclusion of a housekeeping genes in the analysis and the
assumption that expression levels of housekeeping genes
did not vary among different subject populations. Third,
comparisons of ratios or combinations of ratios may
more accurately identify cellular phenotypes that may
contribute to disease. For example, a ratio containing
one gene in the numerator that is over-expressed in the
case cohort relative to the control cohort and one gene
in the denominator that is under-expressed in the case
cohort relative to the control cohort should produce a
greater ratio value difference between individuals in the
two cohorts than a single expression value. Fourth,
ANAPC1, RANGAP1, and LEPREL4 genes encode
unique proteins and each participates in mitosis [28-33].
Thus, a defect in expression of any one of these genes
could produce a common cellular phenotype; a defect in
mitosis, and for example, one subject with a given dis-
ease may exhibit a deficiency in expression of ANAPC1
while a second individual with the same disease may ex-
hibit a deficiency in expression of RANGAP1 and a third
with the same disease may exhibit a defect in LEPREL4
expression levels. Any of these defects has the potential























































0.033 0.0042 0.50 0.0002 0.015 0.0002 0.0086 0.045 0.31 0.0018 0.016 0.026 0.034
0.022 0.0041 0.55 0.0001 0.014 0.0002 0.0082 0.042 0.56 0.0016 0.010 0.014 0.017
0.034 0.0025 0.95 0.0002 0.016 0.0001 0.0062 0.046 0.66 0.0009 0.015 0.015 0.036
0.036 0.0044 0.52 0.0004 0.028 0.0002 0.0082 0.027 0.64 0.0019 0.016 0.024 0.035
0.056 0.0026 0.55 0.0004 0.026 0.0002 0.0152 0.047 0.52 0.0020 0.017 0.027 0.032
rs. Expression levels of 44 target genes were determined by
els of 25 genes are shown; expression levels of the remainder were
expressed as transcript levels of individual genes relative to transcript
tified that showed statistically significant (p-value < 0.05 after






















































































Figure 2 Discrimination of IBD from CTRL and IBS from CTRL
using the ratioscore system. (A) Ability of a single ratio,
PGK1/POU6F1, to discriminate IBD and CTRL subjects. (B) The most
discriminatory 25 gene-expression ratios were identified to
segregate IBD and CTRL subjects. The ratioscore method was
applied to combine ratio performance into a single discriminator.
(C) Ability of a single ratio, PGK1/POU6F1, to discriminate IBS and
CTRL subjects. (D) The most discriminatory 19 gene-expression ratios
were identified to segregate IBS and CTRL subjects. The ratioscore
method was applied to combine ratio performance into a single
discriminator * indicates ratios found in both IBD:CTRL and IBS:CTRL
comparisons.
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a given disease. We refer to this as the Ratioscore
Method.
We applied this approach to determine how accurately
it would distinguish subjects with IBD or IBS from
CTRL. First, we identified ratios capable of discriminating
IBD subjects from CTRL. Second, we applied a re-
sampling permutation testing strategy to identify ratios
that consistently displayed high discriminatory power.
Third, we identified the smallest number of ratios produ-
cing the greatest discrimination between two comparator
groups. The single ratio with the greatest discriminatory
power was PGK1/POU6F1 (Figure 2A). Using this ratio,
30% of IBD subjects achieved a ratioscore value higher
than all CTRL subjects and were awarded one point. A
combination of 25 ratios produced a scoring panel
where 100% of CTRL subjects achieved a score of 0 and
94% of IBD subjects achieved a ratio ≥ 1 (Figure 2B).
Thus, we conclude that gene-expression ratios we identi-
fied accurately distinguished IBD subjects from CTRL.
We continued our analysis to determine how well IBS
and CTRL cohorts were differentiated. Interestingly, the
optimum ratio that distinguished the IBD cohort from
the CTRL cohort, PGK1/POU6F1, was also the optimum
ratio that distinguished the IBS cohort from the CTRL
cohort (Figure 2C). We identified a total of 19 ratios that,
in combination, produced a point system whereby 100%
of CTRL subjects achieved a score of 0 and 90% of IBS
subjects achieved a ratio ≥ 1 (Figure 2D). Thus, even
though IBS is generally considered not to be an inflam-
matory disease, we conclude our approach accurately
distinguishes these subjects from the CTRL group.IBS-IBD discrimination based upon the Ratioscore Method
Next, we assessed our ability to distinguish IBS and IBD
cohorts. The optimum ratio we identified was HRAS/TBP,
p-value < 0.0001 (Figure 3A). We identified a total of 25
ratios that, combined, produced a ratioscore whereby
100% of IBD subjects achieved a score of 0 and 92% of
IBS subjects were awarded a ratio ≥ 1 (Figure 3B). Thus,













































Figure 3 Discrimination of IBD from IBS using the Ratioscore
system. (A) Ability of a single ratio, HRAS/TBP, to discriminate IBD
and IBS subjects. (B) The most discriminatory 25 gene-expression
ratios were identified to segregate IBD and IBS subjects. The














































Figure 4 Discrimination of UC from CD using the Ratioscore
system. (A) Ability of a single ratio, POU6F1/ANAPC1, to discriminate
UC and CD subjects. (B) The most discriminatory 20 gene-expression
ratios were identified to segregate UC and CD subjects. The
Ratioscore System was applied to combine ratio performance into
a single discriminator.
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with IBS.UC-CD discrimination disease based upon the Ratioscore
Method
Finally, we determined if our approach accurately discri-
minated between the two inflammatory bowel diseases,
UC and CD. The optimum ratio was POU6F1/ANAPC1,
p-value = 0.003 (Figure 4A). We identified a total of 20
ratios that, in combination, produced a point system that
awarded 100% of UC subjects a score of 0 and 98% of
subjects with CD a ratio ≥ 1 (Figure 4B). Thus, the
Ratioscore Method accurately discriminated between the
two major subclasses: IBD:UC and IBD:CD.Disease discrimination based upon the SVM method
Support Vector Machines (SVM) were also employed to
classify the data into two distinct groups. The inputs for
the SVM were the same ratios used to calculate the
ratioscores. For example, when separating IBS patients
from CTRL subjects, the same 19 ratios of normalized
gene-expression ratios employed to compute the ratio-
score were used as input to the SVM. In the SVM calcu-
lations, we chose the radial basis kernel (RBK) to
perform the kernel trick. This kernel contains a fitting
parameter β. We also used the “soft margin” approach
to the fitting of the hyper-surface that separates the two
groups (cases and controls). This introduced a second
fitting parameter C. Programs written in Mathematica
(Wolfram Research, Inc.) were created and random
training subsets of the two groups were chosen to find
the parameters, β and C. Each training subset consisted
of 60% of the total dataset. The values of the two fitting
Table 3 Overall accuracy in total, training and validation
sets by SVM #2 method
TOTAL SET TRAINING SET VALIDATION SET
Tc* Ti† TOTAL‡ %I§ Tc Ti TOTAL %I Tc Ti TOTAL %I
80% IBS-C (RBF kernel)
152 8 160 5 124 3 127 2 28 4 33 12
80% IBD-C (RBF kernel)
207 2 209 1 160 0 166 0 41 2 43 4
80% IBD-IBS (RBF kernel)
139 4 143 3 111 1 113 1 27 3 30 10
60% CD-UC (RBF kernel)
77 7 85 9 47 4 51 8 31 3 34 11
60% IBS-C (polynomial)
150 10 160 6 91 4 95 4 59 6 65 9
60% IBD-C (polynomial)
195 14 209 7 88 7 95 7 107 7 114 6
60% IBD-IBS (polynomial)
124 19 143 13 78 8 85 8 46 11 58 19
60% CD-UC (polynomial)
76 9 85 10 47 4 50 8 30 5 35 14
*Tc, total number correct in designated set.
†Ti, total number incorrect in designated set.
‡Total, total number of cases and controls analyzed in designated set.
§% I, incorrect percentage of case:control calls in designated set.
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rect cases and controls were used to define the SVM.
This SVM analysis also accurately discriminated the
different subject groups: (i) IBD and CTRL, (ii) IBS
and CTRL, (iii) IBD and IBS, and (iv) CD and UC
(Table 2).
A second SVM was also employed using LS-SVMLab
software (http://www.esat.kuleuven.ac.be/sista/lssvmlab)
to validate the SVM created with Mathematica. The
procedure for training the SVM followed the following
algorithm:
 X (X = 50%, 60%, and 80%) was randomly selected
from the total set of data and used to train the
SVM.
 On the selected training set, L-fold cross-validation
was performed. In this type of training a certain
fraction of the training set was omitted from
training and the remaining portion of the partial
training set was used to estimate the parameters of
the SVM. This was repeated L times. We used
L = 10. At the completion of the training, a
composite estimate for the parameters was obtained.
 Once the SVM was trained on X% of the total data,
the SVM was applied to the total data set.
Numbers of correct and incorrect classifications were
tabulated for total sets (training and validation), training
sets and validation sets (Table 3). Overall accuracy in the
training sets was greater than overall accuracy of the val-
idation sets. The different training sessions did not pro-
duce much variation in the overall accuracy of the
corresponding validation sets. Using the above algorithm,
two different kernels, a polynomial kernel and Radial Basis
Function (RBF) kernel, were used to create different
machines. Overall, the SVM with the RBF kernels per-
formed somewhat better than the polynomial kernels.
This second SVM was used to discriminate between
the different subject groups, IBD and CTRL, IBS and
CTRL, IBD and IBS, and CD and UC producing levels
of sensitivity and specificity comparable to the Ratio-
score Method or the first SVM method (Table 4). We
determined receiver operating characteristic (ROC)Table 2 Case/control discrimination by support vector machin
Comparison Total # Training set % of total
IBD* vs. CTRL 209 60
IBD* vs. CTRL 160 60
IBD* vs. IBS 143 60
CD* vs. UC 85 60
*Case cohort.
†TP = true positive, FN = false negative, TN = true negative, FP = false positive.curves from data produced by the second SVM method.
The area-under-the-curve (AUC) for each comparison
exceeded 0.96 (Figure 5). The IBD:CTRL comparison
produced the greatest overall accuracy (AUC of 0.997).
Thus, a tiered approach, using either ratioscore or SVM
analysis, can be employed to segregate between IBD and
IBS, first, followed by segregation between CD and UC if
a subject is IBD positive. This approach produced high
levels of sensitivity and specificity at both tiers of the
analysis (Figure 6).
In the above discussion, two support vector machines
were independently created and trained using the ratios
identified by the Ratioscore Method. There was little dif-
ference in the performance of the two machines when
used to classify the different case–control combinations.
One advantage of the SVM-based approach is that it can
be used to classify more than two groups. As an examplees (SVM #1)
Case CTRL
TP # FN # TN # FP #
95 1 100 13
47 0 96 17
45 2 86 10
45 2 31 7
Table 4 Sensitivity and specificity produced by Ratioscore and two SVM methods
Method Ratioscore SVM #1* SVM #2*
Sensitivity Specificity Sensitivity Specificity Sensitivity Specificity
IBD vs. CTRL 0.94 1.00 0.97 0.94 0.99 0.97
IBS vs. CTRL 0.91 1.00 1.00 0.68 0.85 0.99
IBD vs. IBS 0.93 1.00 0.97 0.91 0.92 0.98
CD vs. UC 0.98 1.00 0.94 0.85 0.89 0.92
*Training set = 80% of total, **Training set = 60% of total.
Sensitivity = # true positives/(# true positives + # false negatives).
Specificity = # true negatives/(# true negatives + # false positives).
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for UC (N = 40), CD (N = 46), and CTRL (N = 113).
Using gene ratios determined by comparing CTRL (con-
trols) to UC+CD (cases), the SVM identified 99.8% of
CTRL, 72.5% of UC, and 56.5% of the CD. Hence, the
performance of the tertiary classification was not as
accurate as the binary classifications. However, the ter-
tiary classification was improved by using a different
set of gene ratios, e.g., the union of the set from CTRL
vs. CD, CTRL vs. UC, and CD vs. UC. In this case,
the SVM identified 99.1% of CTRL, 100% of UC, and
84.8% of CD. One factor that may contribute to this
increased accuracy is that the number of gene ratios
used in the training of the SVM was increased from
23 ratios to 49 thus introducing additional parameters
into the SVM structure.
Discussion
IBS and IBD can exhibit overlapping clinical symptoms
making diagnosis difficult without invasive proceduresROC curves

















Figure 5 ROC curves derived from SVM #2 method. Sensitivity,
specificity, and AUC were determined using the Mathematica
program for the following comparisons: IBD:CTRL, IBS:CTRL, IBD:IBS,
and CD:UC.[4,12,34]. Therapy and medication for IBS and IBD are
vastly different and incorrect diagnosis and treatment plans
have significant consequences. Differentiation between UC
and CD can also be difficult, having important implications
when considering medical and operative treatment options.
For example, ASCA and p-ANCA have clinical utility in
diagnosing IBD. ASCA IgA is found in 35-50% of patients
with CD but < 1% of patients with UC. ASCA IgG is found
in 50-80% of patients with CD but only 20% of patients
with UC. In contrast, atypical p-ANCA is found in 70% of
UC patients but only 20% of CD patients [19]. Here, we de-
scribe a relatively non-invasive procedure capable of ac-
curately discriminating between (a) IBS and IBD, and (b)
the two forms of IBD, UC and CD, using three inde-
pendent methods based upon transcript levels in blood
of a discrete set of genes. Each method employs the
same input, which are multiple ratios of expression levels
of two genes. The analytic methods, ratioscore, two
SVM methods, and logistic regression, produce similar
levels of overall accuracy determined by ROC curves
which exceed 95%. We have summarized the overall
process of going from the raw samples to classification
in Figure 7.
In contrast, biomarkers for IBS are non-existent and
diagnosis largely depends upon the absence ofProposed Tiered Analysis
Comparison #1
IBD vs IBS
+ = presence of IBD - = presence of IBS
SVM: sensitivity = 0.92, specificity = 0.98
ratioscore: sensitivity = 0.93, specificity = 1.00
Comparison #2, if IBD+
CD vs UC
+ = presence of CD - = presence of UC
SVM: sensitivity = 0.89, specificity = 0.92
ratioscore: sensitivity = 0.98, specificity = 1.00
Figure 6 Proposed tiered analyses to discriminate subjects with





























Figure 7 A flow chart of the processing of the data and creation of the classifiers.
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experimental biomarkers to distinguish UC and CD
clearly do not perform with the same degree of accuracy
as experimental approaches described here. Thus, we
propose these gene expression ratio tests using the
Ratioscore Method, SVM, or logistic regression for
analysis represent simple non-invasive tests that could
accurately classify patients to IBS or IBD categories
and IBD patients to UC or CD categories even without
colonoscopy or sigmoidoscopy and tissue biopsy.
UC and CD are chronic inflammatory autoimmune
diseases. Using various strategies, numerous studies
have identified unique gene-expression signatures in
blood or peripheral blood mononuclear cells (PBMC)
associated with different autoimmune diseases [22].
Some are unique to a single autoimmune disease,
some discriminate between two autoimmune diseases
and some are shared among multiple autoimmune dis-
eases. Thus perhaps it is not too surprising that we
could employ a similar strategy to identify gene-
expression signatures capable of discriminating the two
forms of IBD, UC and CD, or IBD from CTRL or IBD
from IBS. Somewhat surprising is that IBS can be
readily distinguished from CTRL. IBS is a disorder
whose etiology and pathogenic mechanisms are incom-
pletely understood [4]. Our results clearly demonstrate
that IBS possesses an underlying gene-expression sig-
nature. One possibility is that IBS possesses an
unrecognized mucosal pathology sensed by the im-
mune system and expressed by changes in transcript
levels of specific genes. Another possibility is that IBS
generates expression of cytokines, chemokines, adhe-
sion molecules, neurotransmitters or other mediators
read by the immune system. In support of this notion,
over-expression of PGK1 is associated with IBS, CeD,
CD, and UC and PGK1 is known to be induced by
hypoxia and may be induced by other forms of stress,
inflammation or generalized mucosal irritation [35].
Further, ABR, ACTR1A, EXT2, HRAS, and KRAS are
over-expressed in both IBS and CeD but not CD and
UC. In contrast, APOBEC3F, ASL and SPIB are under-
expressed in CD and UC, but not IBS and CeD. Thus,
the IBS gene-expression signature is more similar to
the CeD gene-expression signature and the UC signa-
ture is more similar to the CD signature. It is uncer-
tain if this suggests that IBS may bear additional
relationships to CeD. An improved understanding of
mechanisms producing differences in levels of specific
gene transcripts in IBS may further our understanding
of the pathogenesis of IBS.
Conclusions
Limitations to our study include selection of patients
with pre-existing diagnoses of IBS and IBD, as this maynot completely represent patients in the general popula-
tion in whom these tests may be performed. However,
in other studies we have shown that subjects with clin-
ically isolated syndrome, a precursor of multiple scler-
osis, who progress to a diagnosis of multiple sclerosis
score positive in ratioscore- or SVM-based analyses,
similar to those described here. This may suggest that
subjects with initial clinical symptoms associated with
IBD or IBS, CD or UC, may be discriminated by this
approach. Future longitudinal approaches are planned
to evaluate utility of these tests. Additional methods,
such as analysis of gene-expression ratios in multi-
dimensional space rather than binary space may im-
prove the diagnostic capabilities of these tests. We
employed three independent approaches to evaluate
the ability of gene-expression ratios to discriminate
subjects with gastro-intestinal diseases with overlapping
clinical symptoms and each produced high degrees of
specificity and sensitivity. Thus, these minimally inva-
sive tests may assist in excluding or establishing a
diagnosis of IBS or IBD, CD or UC.
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